Current concepts in cryptococcosis

Eur J Clin Microbiol Infect Dis. 1989 May;8(5):457-65. doi: 10.1007/BF01964060.

Abstract

Cryptococcus neoformans has become an increasingly important pathogen. Cryptococcosis is an important cause of morbidity and mortality in immunocompromised hosts and is the second most common fungal infection complicating AIDS. In recent years, research has focused on the host defenses against Cryptococcus and has led to an improved understanding of the capsular virulence of the organism, the mechanisms of T-cell defenses, and the role of phagocytic cells in the fungistasis and killing of cryptocci. Amphotericin B with or without flucytosine has clearly improved treatment of cryptococcosis, but therapy is associated with significant toxicity. Current investigation is focused on the triazoles, which may offer improved therapy for cryptococcosis. In this report, we review recent developments in the understanding of the host defenses against Cryptococcocus and discuss current recommendations for the management of cryptococcosis.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Acquired Immunodeficiency Syndrome / complications
  • Amphotericin B / therapeutic use
  • Antifungal Agents / therapeutic use
  • Cryptococcosis* / complications
  • Cryptococcosis* / drug therapy
  • Cryptococcosis* / immunology
  • Cryptococcosis* / microbiology
  • Cryptococcus neoformans / pathogenicity
  • Humans
  • Immune Tolerance
  • Prognosis
  • Triazoles / therapeutic use
  • Virulence

Substances

  • Antifungal Agents
  • Triazoles
  • Amphotericin B